Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.

Laverde D, Probst I, Romero-Saavedra F, Kropec A, Wobser D, Keller W, Grohmann E, Huebner J.

J Infect Dis. 2017 Jun 15;215(12):1836-1845. doi: 10.1093/infdis/jix227.

PMID:
28863473
2.

Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria.

Rossmann FS, Laverde D, Kropec A, Romero-Saavedra F, Meyer-Buehn M, Huebner J.

PLoS One. 2015 Feb 23;10(2):e0118405. doi: 10.1371/journal.pone.0118405. eCollection 2015.

3.

In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens.

Rossmann FS, Kropec A, Laverde D, Saaverda FR, Wobser D, Huebner J.

Infection. 2015 Apr;43(2):169-75. doi: 10.1007/s15010-014-0706-1. Epub 2014 Nov 27.

4.

Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteria.

Laverde D, Wobser D, Romero-Saavedra F, Hogendorf W, van der Marel G, Berthold M, Kropec A, Codee J, Huebner J.

PLoS One. 2014 Oct 21;9(10):e110953. doi: 10.1371/journal.pone.0110953. eCollection 2014.

5.

Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations.

Hufnagel M, Sixel K, Hammer F, Kropec A, Sava IG, Theilacker C, Berner R, Huebner J.

Infection. 2014 Aug;42(4):749-55. doi: 10.1007/s15010-014-0628-y. Epub 2014 May 23.

PMID:
24854332
6.

Cell-wall glycolipid mutations and their effects on virulence of E. faecalis in a rat model of infective endocarditis.

Haller C, Berthold M, Wobser D, Kropec A, Lauriola M, Schlensak C, Huebner J.

PLoS One. 2014 Mar 17;9(3):e91863. doi: 10.1371/journal.pone.0091863. eCollection 2014.

7.

Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.

Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB.

Clin Infect Dis. 2012 Nov;55(9):1188-97. doi: 10.1093/cid/cis624. Epub 2012 Jul 17.

8.

Light fluorous synthesis of glucosylated glycerol teichoic acids.

Hogendorf WF, Kropec A, Filippov DV, Overkleeft HS, Huebner J, van der Marel GA, Codée JD.

Carbohydr Res. 2012 Jul 15;356:142-51. doi: 10.1016/j.carres.2012.02.023. Epub 2012 Mar 6.

PMID:
22429772
9.

Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid.

Theilacker C, Kropec A, Hammer F, Sava I, Wobser D, Sakinc T, Codée JD, Hogendorf WF, van der Marel GA, Huebner J.

J Infect Dis. 2012 Apr 1;205(7):1076-85. doi: 10.1093/infdis/jis022. Epub 2012 Feb 23.

PMID:
22362863
10.

Large-scale screening of a targeted Enterococcus faecalis mutant library identifies envelope fitness factors.

Rigottier-Gois L, Alberti A, Houel A, Taly JF, Palcy P, Manson J, Pinto D, Matos RC, Carrilero L, Montero N, Tariq M, Karsens H, Repp C, Kropec A, Budin-Verneuil A, Benachour A, Sauvageot N, Bizzini A, Gilmore MS, Bessières P, Kok J, Huebner J, Lopes F, Gonzalez-Zorn B, Hartke A, Serror P.

PLoS One. 2011;6(12):e29023. doi: 10.1371/journal.pone.0029023. Epub 2011 Dec 15.

11.

Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections.

Kropec A, Sava IG, Vonend C, Sakinc T, Grohmann E, Huebner J.

Microbiology. 2011 Dec;157(Pt 12):3429-34. doi: 10.1099/mic.0.053207-0. Epub 2011 Sep 8.

PMID:
21903755
12.

Automated solid phase synthesis of teichoic acids.

Hogendorf WF, Meeuwenoord N, Overkleeft HS, Filippov DV, Laverde D, Kropec A, Huebner J, Van der Marel GA, Codée JD.

Chem Commun (Camb). 2011 Aug 21;47(31):8961-3. doi: 10.1039/c1cc13132j. Epub 2011 Jul 6.

PMID:
21734985
13.

Deletion of the glycosyltransferase bgsB of Enterococcus faecalis leads to a complete loss of glycolipids from the cell membrane and to impaired biofilm formation.

Theilacker C, Sava I, Sanchez-Carballo P, Bao Y, Kropec A, Grohmann E, Holst O, Huebner J.

BMC Microbiol. 2011 Apr 6;11:67. doi: 10.1186/1471-2180-11-67.

14.

Serodiversity of opsonic antibodies against Enterococcus faecalis--glycans of the cell wall revisited.

Theilacker C, Kaczyński Z, Kropec A, Sava I, Ye L, Bychowska A, Holst O, Huebner J.

PLoS One. 2011 Mar 18;6(3):e17839. doi: 10.1371/journal.pone.0017839.

15.

Enterococcal surface protein contributes to persistence in the host but is not a target of opsonic and protective antibodies in Enterococcus faecium infection.

Sava IG, Heikens E, Kropec A, Theilacker C, Willems R, Huebner J.

J Med Microbiol. 2010 Sep;59(Pt 9):1001-4. doi: 10.1099/jmm.0.020578-0. Epub 2010 Jun 3.

PMID:
20522627
16.

Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Gening ML, Maira-Litrán T, Kropec A, Skurnik D, Grout M, Tsvetkov YE, Nifantiev NE, Pier GB.

Infect Immun. 2010 Feb;78(2):764-72. doi: 10.1128/IAI.01093-09. Epub 2009 Nov 30.

17.

Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis.

Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, Holst O, Huebner J.

Mol Microbiol. 2009 Feb;71(4):1055-69. doi: 10.1111/j.1365-2958.2009.06587.x.

18.

Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid.

Theilacker C, Kaczynski Z, Kropec A, Fabretti F, Sange T, Holst O, Huebner J.

Infect Immun. 2006 Oct;74(10):5703-12.

19.

Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides.

Fabretti F, Theilacker C, Baldassarri L, Kaczynski Z, Kropec A, Holst O, Huebner J.

Infect Immun. 2006 Jul;74(7):4164-71.

20.

The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB.

J Infect Dis. 2005 Dec 1;192(11):2012-9. Epub 2005 Nov 1.

PMID:
16267775
21.

In vitro assessment of the host response against Enterococcus faecalis used in probiotic preparations.

Kropec A, Hufnagel M, Zimmermann K, Huebner J.

Infection. 2005 Oct;33(5-6):377-9.

PMID:
16258871
22.

Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection.

Kropec A, Maira-Litran T, Jefferson KK, Grout M, Cramton SE, Götz F, Goldmann DA, Pier GB.

Infect Immun. 2005 Oct;73(10):6868-76.

23.

Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.

Maira-Litrán T, Kropec A, Goldmann DA, Pier GB.

Infect Immun. 2005 Oct;73(10):6752-62. Erratum in: Infect Immun. 2005 Nov;73(11):7789.

24.

Naturally acquired antibodies against four Enterococcus faecalis capsular polysaccharides in healthy human sera.

Hufnagel M, Kropec A, Theilacker C, Huebner J.

Clin Diagn Lab Immunol. 2005 Aug;12(8):930-4.

25.

Rationale for the development of immunotherapy regimens against enterococcal infections.

Theilacker C, Krueger WA, Kropec A, Huebner J.

Vaccine. 2004 Dec 6;22 Suppl 1:S31-8. Review.

PMID:
15576199
26.

Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide.

Maira-Litran T, Kropec A, Goldmann D, Pier GB.

Vaccine. 2004 Feb 17;22(7):872-9. Review.

PMID:
15040940
27.

Opsonophagocytic assay as a potentially useful tool for assessing safety of enterococcal preparations.

Hufnagel M, Koch S, Kropec A, Huebner J.

Int J Food Microbiol. 2003 Dec 1;88(2-3):263-7.

PMID:
14596999
28.

Routine surface disinfection in health care facilities: should we do it?

Allerberger F, Ayliffe G, Bassetti M, Braveny I, Bucher A, Damani N, Daschner F, Dettenkofer M, Ezpeleta C, Gastmeier P, Geffers C, Giamarellou H, Goldman D, Grzesiowski P, Gubina M, Haanen PE, Haydouchka I, Hübner J, Kalenic S, Van Knippenberg-Gordebeke G, Kranenburg AM, Krcmery V, Kropec A, Krüger W, Lemmen S, Mayhall CG, Meester M, Mehtar S, Munzinger J, Muzlovic I, Ojajarvi J, Rüden H, Scott G, Shah P, Tambic-Andraszevic A, Unertl K, Voss A, Weist K.

Am J Infect Control. 2002 Aug;30(5):318-9. No abstract available.

PMID:
12163869
29.

Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide.

Maira-Litrán T, Kropec A, Abeygunawardana C, Joyce J, Mark G 3rd, Goldmann DA, Pier GB.

Infect Immun. 2002 Aug;70(8):4433-40.

30.

In vitro susceptibility to everninomycin of gram-positive nosocomial pathogens isolated from intensive care units in Germany.

Kropec A, Frank U, Jonas D, Thriene W, Schmidt-Eisenlohr E, Daschner FD.

Chemotherapy. 2001 Jan-Feb;47(1):15-8.

PMID:
11125228
31.

Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events.

Schulgen G, Kropec A, Kappstein I, Daschner F, Schumacher M.

J Clin Epidemiol. 2000 Apr;53(4):409-17.

PMID:
10785572
32.

Differential cytokine production in stimulated blood cultures from intensive care patients with bacterial infections.

Mitov IG, Kropec A, Benzing A, Just H, Garotta G, Galanos C, Freudenberg M.

Infection. 1997 Jul-Aug;25(4):206-12.

PMID:
9266258
33.

Scoring system for nosocomial pneumonia in ICUs.

Kropec A, Schulgen G, Just H, Geiger K, Schumacher M, Daschner F.

Intensive Care Med. 1996 Nov;22(11):1155-61.

PMID:
9120106
34.

Cross infections due to coagulase-negative staphylococci in high-risk patients.

Hübner J, Kropec A.

Zentralbl Bakteriol. 1995 Dec;283(2):169-74. Review.

PMID:
8825108
35.

Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing of Escherichia coli by human neutrophils.

Kropec A, Lemmen SW, Grundmann HJ, Engels I, Daschner FD.

Infection. 1995 Sep-Oct;23(5):298-300.

PMID:
8557389
36.

Glycopeptides in the treatment of staphylococcal infections.

Daschner FD, Kropec A.

Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S12-7. Review.

PMID:
7729466
37.

Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci.

Kropec A, Lemmen S, Wursthorn M, Daschner FD.

Infection. 1994 Jul-Aug;22(4):306-8.

PMID:
8002095
38.

Endemic nosocomial transmission of Staphylococcus epidermidis bacteremia isolates in a neonatal intensive care unit over 10 years.

Huebner J, Pier GB, Maslow JN, Muller E, Shiro H, Parent M, Kropec A, Arbeit RD, Goldmann DA.

J Infect Dis. 1994 Mar;169(3):526-31.

PMID:
8158023
39.

MIC and serum bactericidal activity of clindamycin against methicillin-resistant and -sensitive staphylococci.

Lemmen S, Kropec A, Engels I, Busse A, Daschner FD.

Infection. 1993 Nov-Dec;21(6):407-9.

PMID:
8132374
40.

Serum bactericidal activity after administration of four cephalosporins in healthy volunteers.

Lemmen S, Kropec A, Engels I, Busse A, Daschner FD.

Eur J Clin Microbiol Infect Dis. 1993 Nov;12(11):856-60.

PMID:
8112358
41.

Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen.

Grundmann H, Kropec A, Hartung D, Berner R, Daschner F.

J Infect Dis. 1993 Oct;168(4):943-7.

PMID:
8376840
42.

In vitro activity of sodium bisulfite and heparin against staphylococci: new strategies in the treatment of catheter-related infection.

Kropec A, Huebner J, Frank U, Lemmen S, Hirt U, Daschner FD.

J Infect Dis. 1993 Jul;168(1):235-7.

PMID:
8515118
43.

In vitro activity of vancomycin and teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis colonizing catheters.

Kropec A, Huebner J, Wursthorn M, Daschner FD.

Eur J Clin Microbiol Infect Dis. 1993 Jul;12(7):545-8.

PMID:
8404917
44.

Ribotyping of Pseudomonas aeruginosa strains isolated from surgical intensive care patients.

Gruner E, Kropec A, Huebner J, Altwegg M, Daschner F.

J Infect Dis. 1993 May;167(5):1216-20.

PMID:
8098054
45.

Polymerase chain reaction: detection of varicella-zoster virus.

Fenner T, Kropec A, Hübner J.

J Clin Microbiol. 1993 Feb;31(2):470. No abstract available.

46.

Comparison of three typing methods in hospital outbreaks of Acinetobacter calcoaceticus infection.

Kropec A, Hübner J, Daschner FD.

J Hosp Infect. 1993 Feb;23(2):133-41.

PMID:
8097217
47.

Enhancement of in vitro bactericidal activity of neutrophils from trauma patients in the presence of granulocyte colony-stimulating factor.

Anding K, Kropec A, Schmidt-Eisenlohr E, Benzing A, Geiger K, Daschner F.

Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):121-4.

PMID:
7684679
48.

Exogenous or endogenous reservoirs of nosocomial Pseudomonas aeruginosa and Staphylococcus aureus infections in a surgical intensive care unit.

Kropec A, Huebner J, Riffel M, Bayer U, Benzing A, Geiger K, Daschner FD.

Intensive Care Med. 1993;19(3):161-5.

PMID:
8315124
50.

Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

Hübner J, Hartung D, Kropec A, Daschner FD.

Infection. 1991 May-Jun;19(3):186-9.

PMID:
1889877

Supplemental Content

Loading ...
Support Center